Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04215211

MR Based Survival Prediction of Glioma Patients Using Artificial Intelligence

MR Based Survival Prediction of Patients With Primary Glioma Ssing Deep Learning or Machine Learning

Status
Recruiting
Phase
Study type
Observational
Enrollment
2,500 (estimated)
Sponsor
The First Affiliated Hospital of Zhengzhou University · Academic / Other
Sex
All
Age
1 Year – 90 Years
Healthy volunteers
Not accepted

Summary

This registry aims to collect clinical, molecular and radiologic data including detailed survival data, clinical parameters, molecular pathology (1p/19q codeletion, MGMT methylation, IDH and TERTp mutations, etc) and conventional/advanced/new MR sequences (T1, T1c, T2, FLAIR, ADC, DTI, PWI, etc) of patients with primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine algorithms that able to predict patients' survivals in the frame of molecular pathology or subgroups of gliomas.

Detailed description

Non-invasive and precise prediction for survivals of glioma patients is challenging. With the development of artificial intelligence, much more potential lies in the preoperative conventional/advanced MR imaging (T1 weighted imaging, T2 weighted imaging, FLAIR, contrast-enhanced T1 weighted imaging, diffusion-weighted imaging, and perfusion imaging) could be excavated to aid prediction of patients' prognosis in the frame of molecular pathology of gliomas. The creation of a registry for primary glioma with detailed survival data, molecular pathology, radiological data and with sufficient sample size for deep learning (\>1000) provides opportunities for personalized prediction of survival of glioma patients with non-invasiveness and precision.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTSurvival prediction for glioma patientsSurvival prediction of glioma patients in the frame of molecular pathology by leveraging AI

Timeline

Start date
2017-01-01
Primary completion
2027-01-01
Completion
2027-06-01
First posted
2020-01-02
Last updated
2021-02-08

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04215211. Inclusion in this directory is not an endorsement.